Form 4: Ionis Pharmaceuticals CEO Acquires Shares Under Employee Stock Purchase Plan

CEO Brett P. Monia acquired 538 shares of Ionis Pharmaceuticals common stock through the company's employee stock purchase plan on February 29, 2024.

Summary

• On February 29, 2024, Brett P. Monia, CEO of Ionis Pharmaceuticals, acquired 538 shares of common stock through the company's Amended and Restated 2000 Employee Stock Purchase Plan.
• The purchase price was $34.425 per share.
• Following the transaction, Monia directly owns 174,289 shares of Ionis Pharmaceuticals.
• These shares may not be sold until August 31, 2024.

Sentiment

Score: 6

Explanation: The document reflects a neutral sentiment as it reports a routine stock purchase by the CEO. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Positives

• The CEO's participation in the employee stock purchase plan demonstrates confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.

Comparison to Industry Standards

• Executive stock ownership is a common practice in publicly traded companies, including pharmaceutical firms like Alnylam Pharmaceuticals and Biogen.
• Employee stock purchase plans are also standard benefits offered to employees in these companies.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals the CEO's confidence in the company.

Key Dates